Dr. Figlin on Sunitinib for Patients With RCC

Robert Figlin, MD
Published: Monday, Nov 09, 2015



Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, discusses newer methods of administering sunitinib (Sutent) to patients with renal cell carcinoma (RCC).

Several discoveries have been made in RCC, Figlin explains, with regard to existing TKIs and emerging agents that are changing the treatment paradigm. For example, there have been new methods for administering sunitinib, which has been approved for patients since 2006. Sunitinib was previously administered on a regimen consisting of 4 weeks of treatment and 2 weeks of rest.

Now, giving patients the same dosage to patients on a schedule of 2 weeks of treatment and 1 week of rest is equally effective, decreases toxicities, and allows patients to have better quality of life, Figlin says.
 
SELECTED
LANGUAGE


Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, discusses newer methods of administering sunitinib (Sutent) to patients with renal cell carcinoma (RCC).

Several discoveries have been made in RCC, Figlin explains, with regard to existing TKIs and emerging agents that are changing the treatment paradigm. For example, there have been new methods for administering sunitinib, which has been approved for patients since 2006. Sunitinib was previously administered on a regimen consisting of 4 weeks of treatment and 2 weeks of rest.

Now, giving patients the same dosage to patients on a schedule of 2 weeks of treatment and 1 week of rest is equally effective, decreases toxicities, and allows patients to have better quality of life, Figlin says.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x